Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.19
Views: 502
Rating:

Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA

Prof Stephen Schuster speaks to ecancer at the 2019 ASH meeting in Orlando about the use of mosunetuzumab in patients with non-Hodgkin lymphoma.

He describes the design of this study, along with the results achieved and toxicities observed with the action of this dual-targeting antibody.

Prof Schuster elaborates on this unmet need for patients who do not respond to CAR T-cell therapy.

He concludes by discussing the future use of this drug which is easily accessible due to its off-the-shelf availability.

Watch the press conference here

Read more about the study here

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation